Overall, ADMAIORA will target a ground-breaking paradigm that may revolutionize OA treatment. Within the project time-frame (4 years) the target is to achieve a 60% reduction of degeneration in OA animal models treated with the ADMAIORA technologies, with respect to control (untreated) ones, after 4 weeks, and a 90% reduction after 3 months. To achieve this ambitious objective the Consortium will evolve and merge technologies that already showed a high potential as experimental proof of concepts and will bring them at a preclinical level.
The ADMAIORA Consortium will develop biosynthetic hydrogels embedded with carbon-based nanomaterials, conferring higher mechanical and lubrication properties, and piezoelectric nanoparticles enabling responsivity to remote wireless ultrasound waves. Stem cells derived from autologous adipose tissue, which already demonstrated anti-inflammatory and regenerative properties, will be entrapped in the hydrogels. Materials and cells will be delivered in situ through an innovative handheld 3D bioprinter, embedded in an arthroscopic tool. A custom brace will be designed and equipped with ultrasound probes for both monitoring the joint status and stimulating the implanted piezoelectric nanobiomaterial. A dedicated App will allow a direct connection between patient and physician in an Internet of Things framework.